Visual Impairment News and Research

Latest Visual Impairment News and Research

AIDS patients at increased risk of developing intermediate-stage AMD

Patients with acquired immunodeficiency syndrome (AIDS) have a four-fold increase in their risk of developing intermediate-stage age-related macular degeneration (AMD) compared to people of the same age who are not infected with HIV, according to results from the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) presented today at the 2015 ARVO Annual Meeting in Denver, CO.

5 May 2015

Supporting people with macular degeneration: an interview with Dennis Lewis, AMD Alliance International

Once depression sets in, it's very hard to combat. Combinations of medication and talking therapy can help deal with that, but it can be tough when people reach rock bottom and that certainly does happen with macular degeneration...

28 Apr 2015

TSRI study provides new insight into preventing diseases that cause vision loss in adults

A new study from scientists at The Scripps Research Institute shows that nerve cells and blood vessels in the eye constantly "talk" to each other to maintain healthy blood flow and prevent disease.

28 Apr 2015

Researchers discover retina protein crucial for vision

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the LSU Health New Orleans Neuroscience Center of Excellence, discovered a protein in the retina that is crucial for vision. The paper reports, for the first time, the key molecular mechanisms leading to visual degeneration and blindness.

5 Mar 2015

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO).

26 Feb 2015

Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease (PD) often have difficulties with visual acuity in low-contrast images. Because they may have normal high-contrast vision, this is often overlooked during routine eye exams. In the current issue of the Journal of Parkinson's Disease, researchers report that PD patients had significantly worse vision for low-contrast images at close (40 cm) and far (2 m) distances. Even for high-contrast images, PD patients' vision was deficient at far distances.

26 Feb 2015

RowanSOM researcher awarded NINDS grant to develop stem cell-based therapy for Canavan disease

Paola Leone, PhD, the director of the Cell and Gene Therapy Center and a professor of Cell Biology at the Rowan University School of Osteopathic Medicine, has been awarded a three-year, $477,000 grant from the National Institute of Neurological Disorders and Stroke to develop a stem cell-based therapy for Canavan disease, a rare but devastating neurological disorder in children that typically takes a child's life by age 10.

26 Feb 2015

WHO urges affected countries to increase investment in tackling neglected tropical diseases

WHO urges affected countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low and middle income countries for the period 2015-2030.

19 Feb 2015

Ranibizumab drug reverses diabetes-related blindness

Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the University of Southern California Eye Institute.

19 Feb 2015

OIB Program helps older Californians with blindness to live and work independently

More than ever, older Californians are facing the threat of blindness from age-related eye diseases such as diabetic retinopathy, macular degeneration, cataracts and glaucoma.

12 Feb 2015

RPB co-sponsors major IOM study to promote eye health

Research to Prevent Blindness, the leading nonprofit driver of research toward cures and treatments for all blinding disorders, is co-sponsoring a major Institute of Medicine study entitled "Public Health Approaches to Reduce Vision Impairment and Promote Eye Health."

8 Feb 2015

Many MEN1 tumour types found in children

Most tumour types reported in adult patients with multiple endocrine neoplasia Type-1 can be found in children with the condition, although rarely before the age of 10 years, shows a large study.

30 Jan 2015

Tackling preventable blindness: a House of Commons reception review

“Macular degeneration is not life threatening, but it is life changing,” these were the words of Michael Valenzia, of the Macular Society at the recent House of Commons Reception held by AMD Alliance International.

27 Jan 2015

Scientists explore how the brain adapts to visual restoration

Recent scientific advances have meant that eyesight can be partially restored to those who previously would have been blind for life. However, scientists at the University of Montreal and the University of Trento have discovered that the rewiring of the senses that occurs in the brains of the long-term blind means that visual restoration may never be complete.

19 Jan 2015

Added benefit of aflibercept not proven in patients with diabetic macular oedema

Since August 2014, aflibercept (trade name Eylea) has been available also for patients with visual impairment due to diabetic macular oedema (DMO). The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy.

15 Dec 2014

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

10 Dec 2014

New study describes revolutionary novel device that has potential to treat eye diseases

The aging process affects everything from cardiovascular function to memory to sexuality. Most worrisome for many, however, is the potential loss of eyesight due to retinal degeneration.

3 Dec 2014

Monash Vision Group moves a step closer to Bionic Eye clinical trials

The Monash Vision Groupmoves a step closer to clinical trials of its Bionic Eye, thanks to landmark donations from two respected business leaders.

3 Dec 2014

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO).

1 Dec 2014

HIV drugs could be harnessed to treat leading cause of blindness

An established class of drugs, traditionally used to control HIV/AIDS infections, could soon be harnessed to treat the leading cause of blindness and visual impairment in the UK, for which currently there exists no cure.

27 Nov 2014

Visual Impairment News and Research

Latest Visual Impairment News and Research

AIDS patients at increased risk of developing intermediate-stage AMD

Supporting people with macular degeneration: an interview with Dennis Lewis, AMD Alliance International

TSRI study provides new insight into preventing diseases that cause vision loss in adults

Researchers discover retina protein crucial for vision

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

RowanSOM researcher awarded NINDS grant to develop stem cell-based therapy for Canavan disease

WHO urges affected countries to increase investment in tackling neglected tropical diseases

Ranibizumab drug reverses diabetes-related blindness

OIB Program helps older Californians with blindness to live and work independently

RPB co-sponsors major IOM study to promote eye health

Many MEN1 tumour types found in children

Tackling preventable blindness: a House of Commons reception review

Scientists explore how the brain adapts to visual restoration

Added benefit of aflibercept not proven in patients with diabetic macular oedema

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

New study describes revolutionary novel device that has potential to treat eye diseases

Monash Vision Group moves a step closer to Bionic Eye clinical trials

Eylea receives Health Canada approval for treatment of CRVO and DME

HIV drugs could be harnessed to treat leading cause of blindness

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Visual Impairment News and Research

Latest Visual Impairment News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in